US Researchers Complete Study on Nerve Agent Treatment

Researchers have completed a Phase I study with atropine sulphate delivered from a MicroDose proprietary dry powder inhaler to combat the effects of nerve agent poisoning.

Researchers at the University of Pittsburgh Medical Center in the US have successfully completed a Phase I study with atropine sulphate delivered from a MicroDose proprietary dry powder inhaler to combat the effects of nerve agent poisoning.

The open-label, active-controlled and crossover study involved 17 adult healthy subjects and demonstrated the pharmacokinetics of atropine dry powder inhalation.

Robert Cook, senior director of the MicroDose product commercialisation group, said that follow-up trials will further demonstrate the ability to achieve atropine bioavailability from the MicroDose inhaler. "The inhaled route offers a non-invasive alternative by delivering atropine directly to the lungs where local complications